Art. -Nr.: HY-100744

AS8351

(Synonyms: NSC51355)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

AS8351 (NSC51355) is a KDM5B inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.88%
CAS. Nr.: 796-42-9
Formel: C₁₇H₁₃N₃O₂
Molecular Weight:291.30

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

AS8351 Chemical Structure

CAS. Nr.: 796-42-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

AS8351 (NSC51355) is a KDM5B inhibitor, which can induce and sustain active chromatin marks to facilitate the induction of cardiomyocyte-like cells^[1].

IC₅₀ & Target

KDM5

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.2 μM Compound: NIH	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay Antiproliferative activity at human A549 cells after 72 hrs by MTT assay	[PMID: 22861499]
DMS-53	IC₅₀	1.1 μM Compound: NIH	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay	[PMID: 22861499]
HEL	EC₅₀	0.06 μg/mL Compound: 7	Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HEL	EC₅₀	0.14 μg/mL Compound: 7	Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HEL	EC₅₀	0.4 μg/mL Compound: 7	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HEL	EC₅₀	0.4 μg/mL Compound: 7	Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against TK(-) aciclovir-resistant Human herpesvirus 1 strain KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HeLa	EC₅₀	>0.04 μg/mL Compound: 7	Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HeLa	EC₅₀	>0.04 μg/mL Compound: 7	Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HeLa	EC₅₀	>0.04 μg/mL Compound: 7	Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
HUVEC	IC₅₀	20.1 μM Compound: 311	Antiproliferative activity against HUVEC after 22 to 72 hrs by MTT assay Antiproliferative activity against HUVEC after 22 to 72 hrs by MTT assay	[PMID: 27187862]
MRC5	IC₅₀	>10 μM Compound: NIH	Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay Antiproliferative activity at human MRC5 cells after 72 hrs by MTT assay	[PMID: 22861499]
MT4	CC₅₀	0.1 μg/mL Compound: 7	Cytotoxicity against Homo sapiens (human) MT4 cells Cytotoxicity against Homo sapiens (human) MT4 cells	10.1007/s00044-011-9662-9
MT4	EC₅₀	>0.1 μg/mL Compound: 7	Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus 1 IIIB infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
MT4	EC₅₀	>0.1 μg/mL Compound: 7	Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human immunodeficiency virus type 2 (ISOLATE ROD) infected human MT4 cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
SK-N-MC	IC₅₀	0.3 μM Compound: NIH	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 19601577]
SK-N-MC	IC₅₀	0.3 μM Compound: NIH	Antiproliferative activity against human SK-N-MC cells Antiproliferative activity against human SK-N-MC cells	[PMID: 19601577]
SK-N-MC	IC₅₀	0.5 μM Compound: 311	Antiproliferative activity against human SK-N-MC cells after 22 to 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 22 to 72 hrs by MTT assay	[PMID: 27187862]
SK-N-MC	IC₅₀	0.5 μM Compound: H2NIH (311)	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 19216562]
SK-N-MC	IC₅₀	0.59 μM Compound: H2NIH	Antiproliferative activity against human SK-N-MC cells by MTT assay Antiproliferative activity against human SK-N-MC cells by MTT assay	[PMID: 17963372]
SK-N-MC	IC₅₀	0.71 μM Compound: NIH	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 17602603]
SK-N-MC	IC₅₀	1 μM Compound: NIH	Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay	[PMID: 19601577]
SK-N-MC	IC₅₀	1.1 μM Compound: NIH	Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 22861499]
SK-N-MC	IC₅₀	1.3 μM Compound: 311	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay	[PMID: 22858101]
SK-N-MC	IC₅₀	2.53 μM Compound: NIH	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay	[PMID: 21846118]
SK-N-MC	IC₅₀	2.53 μM Compound: NIH	Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23276209]
Vero	EC₅₀	>0.8 μg/mL Compound: 7	Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>0.8 μg/mL Compound: 7	Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>0.8 μg/mL Compound: 7	Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>0.8 μg/mL Compound: 7	Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9
Vero	EC₅₀	>0.8 μg/mL Compound: 7	Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathicity	10.1007/s00044-011-9662-9

In Vitro

AS8351 affects epigenetic modifications by competing with α-ketoglutarate (α-KG) for chelating iron [Fe(II)] in certain epigenetic enzymes, such as the JmjC domain-containing histone demethylases (JmjC-KDMs) that require α-KG and iron as co-factors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 796-42-9
Appearance Solid
Molecular Weight 291.30
Formel C₁₇H₁₃N₃O₂
Color Light yellow to yellow
SMILES

O=C(C1=CC=NC=C1)N/N=C/C2=C3C=CC=CC3=CC=C2O
Synonyms

NSC51355
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Clin Exp Med

Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]

2025 Nov 25;26(1):33. PMID: 41286164

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 150 mg/mL (514.93 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4329 mL

17.1644 mL

34.3289 mL

5 mM

0.6866 mL

3.4329 mL

6.8658 mL

10 mM

0.3433 mL

1.7164 mL

3.4329 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Liu K, et al. Chemical Modulation of Cell Fate in Stem Cell Therapeutics and Regenerative Medicine. Cell Chem Biol. 2016 Aug 18;23(8):893-916. [Content Brief]

[2]. Cao N, et al. Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science. 2016 Jun 3;352(6290):1216-20. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4329 mL	17.1644 mL	34.3289 mL	85.8222 mL
	5 mM	0.6866 mL	3.4329 mL	6.8658 mL	17.1644 mL
	10 mM	0.3433 mL	1.7164 mL	3.4329 mL	8.5822 mL
	15 mM	0.2289 mL	1.1443 mL	2.2886 mL	5.7215 mL
	20 mM	0.1716 mL	0.8582 mL	1.7164 mL	4.2911 mL
	25 mM	0.1373 mL	0.6866 mL	1.3732 mL	3.4329 mL
	30 mM	0.1144 mL	0.5721 mL	1.1443 mL	2.8607 mL
	40 mM	0.0858 mL	0.4291 mL	0.8582 mL	2.1456 mL
	50 mM	0.0687 mL	0.3433 mL	0.6866 mL	1.7164 mL
	60 mM	0.0572 mL	0.2861 mL	0.5721 mL	1.4304 mL
	80 mM	0.0429 mL	0.2146 mL	0.4291 mL	1.0728 mL
	100 mM	0.0343 mL	0.1716 mL	0.3433 mL	0.8582 mL

Keywords

AS8351

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AS8351

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Heterocyclic Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) AS8351

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AS8351

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Heterocyclic Compound Library

Cysteine Targeted Covalent Library

Bioactive Compound Library Max

Epigenetics Compound Library Mini

Bioactive Compound Library

Methylation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) AS8351

Alle Histone Demethylase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AS8351 Related Classifications

HY-100744 Related Classifications